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Previews(blebbistatin) or an inhibitor of LIMK,
a kinase that acts downstream of ROCK
to promote actin assembly, blocked skin
thickening and reduced b-catenin levels
in K14-ROCK:ER mice. Similarly, the in-
crease in collagen deposition was found
to be reduced.
To test whether ROCK activation would
impact tumor growth and progression,
skin papillomas were induced by two-
step chemical tumorigenesis using dime-
thylbenz[a]anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA).
Through a mechanism involving mutation
of HRAS and subsequent MAP-kinase
activation, skin papillomas appear and a
small proportion progress to invasive car-
cinomas. When the inducible ROCK:ER
micewere used in the two-stage chemical
carcinogenesis protocol, induction of
ROCK activity increased total papilloma
burden and accelerated progression to
carcinomas compared with controls.
Moreover, total and nuclear b-catenin
levels were significantly increased in pap-
illomas in the ROCK:ER mice, indicating
that the pathways regulating skin thick-
ening are also important during tumor
progression. Interestingly, the authors
showed that simultaneous treatment of
mouse skin with DMBA/TPA and the
ROCK inhibitor Y-27632 resulted in a
significantly lower papilloma burden anda lower conversion rate. It will be of great
interest to determine the effects of block-
ing ROCK activity on established papillo-
masandcarcinomas. Importantly, Samuel
et al. (2011) provide evidence that ROCK
signaling is frequently upregulated in
human skin carcinomas. Further work will
be required to provide a detailed picture
of the levels of ROCK and ROCK signaling
to tumor grade and to extend these
studies to other tumor types.
Without doubt, Samuel et al. (2011)
have provided strong evidence for ROCK-
mediated intracellular contractility driving
tumorigenesis by affecting ECM deposi-
tion, remodeling, and tissue stiffness.
Importantly, they show that increased
tissue stiffness results from increased
collagen deposition and crosslinking fol-
lowing increased actomyosin contractility
(Figure 1B). Why there is an increased
collagen deposition remains unclear,
whereas the mechanism for an increase in
levels of b-catenin and its transcriptional
activity may depend on increased integrin
signaling (Figure 1B). In the experimental
systemused in thisstudy,elevatedactomy-
osin contractility is generated in the tumor
cells themselves; however, other work
suggests that tumor-associated cells such
as carcinoma-associated fibroblasts can
generate actomyosin contractility for extra-
cellular matrix remodeling (Gaggioli et al.,Cancer Cell2007). Furthermore, there is evidence that
some cancers may harbor mutations that
reduce actomyosin contractility (Brognard
et al., 2011). Thus, the study of the roles of
actomyosin contractility is likely to generate
many new insights into tumor biology.REFERENCES
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Two recent Cancer Cell articles report the discovery of reciprocal feedback regulation between androgenic
and PTEN loss/PI3K-AKT signaling in prostate cancer. Both studies link endocrine regulation with a common
oncogenic pathway, which led to the development of a combination therapeutic approach with immediate
application in prostate cancer.The exquisite sensitivity of the prostate
gland to androgenic steroids has provided
a foothold for the development of sys-temic prostate cancer therapy for more
than seventy years (Huggins and Hodges,
1941). A sustainedstrategic approach thatfocused on inhibiting this unique signaling
pathway led to the use of androgen-depri-
vation and antiandrogenic therapies for19, June 14, 2011 ª2011 Elsevier Inc. 697
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Figure 1. Reciprocal Inhibition Feedback Links AR- and PTEN Loss/
PI3K-AKT Signaling Pathways in Prostate Cancer
As reported in Carver et al. (2011) andMulholland et al. (2011), reciprocal nega-
tive feedback underlies the oncogenic activities of PTEN loss/PI3K-AKT
signaling (depicted as the area inside the dotted ‘‘corners’’). Activation of
PI3K-AKT leads to suppression/subversion of AR signaling through suppres-
sion of HER kinases; upregulation of EGR1 and c-JUN transcriptional coregu-
lators; and upregulation of the Polycomb group protein EZH2. Reciprocal
negative feedback is established, in part, through AR-stimulated, FKBP5-
mediated activation of AKT phosphatase PHLPP. GFs, growth factors.
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These therapies continue to
serve as the standard of
care, although, unfortunately,
antiandrogenic therapies are
not curative; newapproaches
are needed. With the advent
of targeted therapies for can-
cer, antiandrogenic agents
have continued to form the
base on which combination
therapies—including those
that target common onco-
genic signaling activities—
can be developed. In the
case of prostate cancer, this
has proved particularly chal-
lenging because of the ex-
tremely heterogeneous na-
ture of the genetic alterations
that underlie this disease.
A prominent molecular
target for prostate cancer
therapy is the PI3K-AKT
signaling pathway. A recent
study of 218 prostate cancer
tumors showed that 42% ofthe primary tumors and 100% of the
metastasesharboredgenomicaberrations
in that pathway (Taylor et al., 2010). The
best-characterized genetic alteration in
this pathway is in PTEN, which has been
shown to be mutated and/or exhibit loss
of heterozygosity in approximately 15%
of localized prostate cancer and 30% of
metastatic disease (Sarker et al., 2009).
Multiple small-molecule inhibitors of
PI3K-AKT signaling have been developed
and tested clinically. Although the results
of early clinical trials are inconclusive, the
therapeutic activities of PI3K-AKT inhibi-
tors as single agents have generally been
modest in patientswith advancedprostate
cancer. Thus, there is considerable effort
to rationally integrate PI3K-AKT inhibitors
into combination therapy protocols.
In recent issues of Cancer Cell, both
Carver et al. (2011) and Mulholland et al.
(2011) report on having identified recip-
rocal feedback regulation between AR
and PTEN loss/PI3K-AKT signaling in
prostate cancer. By making effective use
of the PB-Cre;Ptenlox/lox mouse model
and carefully annotated human prostate
cancer tissue samples, these two groups
of investigators have made a seminal
contribution to our understanding of the
regulation of growth and survival signaling
in prostate cancer cells and, by extension,698 Cancer Cell 19, June 14, 2011 ª2011 Elsto the rationale for use of specific com-
bination therapy for advanced prostate
cancer.
Using similar experimental approaches,
Carver et al. (2011) and Mulholland et al.
(2011) demonstrated that loss of PTEN
function sets into motion a series of
molecular events that establish a linkage
between two expansive signaling net-
works that exert control over the growth,
survival, and differentiation of prostatic
epithelial cells. Activation of PI3K-AKT
signaling as a result of Pten mutation in
the PB-Cre;Ptenlox/lox mouse leads to
suppression of AR signaling. Transcrip-
tome analysis revealed substantial over-
lap of up- and downregulated genes
between intact male Pten/ mice and
castrated wild-type mice and also dem-
onstrated that PTEN loss is associated
with reduced AR signaling in PTEN-defi-
cient human prostate tumors. These
results, together with those of previous
studies (Gao et al., 2006; Jiao et al.,
2007), show that the loss of PTEN function
and activation of PI3K-AKT signaling
plant the seeds for androgen-independent
prostate cancer growth by establishing
a castrate genetic program.
Using both pharmacologic and genetic
approaches, Carver et al. (2011) and Mul-
holland et al. (2011) showed that differentevier Inc.mechanisms contribute to
the repression of AR output.
Carver et al. (2011) demon-
strated that PI3K-AKT, but
not MEK signaling, is re-
sponsible for inhibiting AR
signaling, and that this inhi-
bition depends on upstream
HER kinase inhibition. Using
a PTEN re-expression ap-
proach, Mulholland et al.
(2011) showed that PTEN
loss may suppress an-
drogen-responsive genes
through upregulation of Egr1
and c-Jun transcriptional cor-
egulators and the catalytic
subunit of Polycomb repres-
sive complex 2, Ezh2. Thus,
PTEN loss can lead to repres-
sion of AR signaling on two
levels: upstream suppression
of MAPK-stimulated HER
kinase, and suppression/sub-
version of AR-mediated tran-
scription through increased
expression of transcriptionalcoregulators and a histone methyltrans-
ferase (Figure 1).
Probing the castration response in PB-
Cre;Ptenlox/lox mice, PB-MYC mice, and
androgen-sensitive prostate cancer cells
(Carver et al., 2011) and analyzing
a double-knockout mutant, PB-Cre;
Ptenlox/lox;Arlox/Y, mouse and human pros-
tate cancer samples (Mulholland et al.,
2011) led to the second crucial surprising
finding—that castration or AR loss
increased AKT phosphorylation. An impor-
tant note is that these two experimental
approaches independently led to the iden-
tification of a reciprocal negative-feedback
signal in thePB-Cre;Ptenlox/loxmodel and in
androgen-sensitive human prostate
cancer cell lines; that signal is AR-stimu-
lated, FKBP5-mediated activation of the
AKT phosphatase PHLPP, which sup-
presses AKT activities (Figure 1).
On the basis of their results, both groups
hypothesized that prostate cancers in
a castrate state (or with low AR levels)
have greater dependency on PTEN loss/
PI3K-AKTsignaling.To test this hypothesis
in vivo, in scientific synchrony, Carver and
colleagues showed that a combination of
BEZ235 (a dual PI3K and mTOR inhibitor)
and castration resulted in dramatic reduc-
tions in tumor volume, in contrast to no
effect of single-pathway therapy, in LNCaP
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responses in the PB-Cre;Ptenlox/lox model;
Mulholland and colleagues demonstrated
that rapamycin (an mTOR inhibitor) treat-
ment of castrated PB-Cre;Ptenlox/lox;
Arlox/Y mice harboring prostate cancer re-
sulted in significantly reduced proliferation
and tumor burden when compared with
castration alone.
The reciprocal negative feedback that
links the AR and PTEN loss/PI3K-AKT
signaling networks is intriguing on many
levels. The inhibitor studies of Carver
et al. (2011) directly link PI3K-AKT
signaling with HER kinase inhibition.
However, the gene expression analysis of
Mulholland et al. (2011) does not exclude
PI3K-AKT-independent, PTEN loss-medi-
ated signaling as a mechanism underlying
upregulation of EGR1, c-JUN, and EZH2,
extending the linkage between the andro-
genic and PTEN loss/PI3K-AKT signaling.
It is well established that AR signaling
promotes the growth and differentiation
of prostate epithelial cells. The precision
and coordination involved in androgenic
regulation of prostatic growth, morpho-
genesis, and cytodifferentiation depends
to a large extent on AR target gene activi-
ties, which are modulated by numerous
coregulators (Lamont and Tindall, 2010).
A recent article showed that the
TMPRSS2-ERG gene fusion product can
disrupt androgenic signaling in prostate
cancer cells through multiple mecha-
nisms, including binding to AR target
genes and induction of EZH2 expression,which in turn can suppress prostate cell
differentiation (Yu et al., 2010). In addition,
under some conditions, PI3K-AKT sig-
naling can enhance AR activities and
induce AR target genes, such as
p21WAF/CIP, which is associated with
androgen-independent growth of prostate
cancer (Lu et al., 2006). In light of the new
knowledge about this mechanistic frame-
work that has resulted from the discovery
of reciprocal negative feedback linking
the AR and PI3K-AKT signaling networks,
it may be possible to better characterize
and delineate additional signaling path-
waysand identifyadditional transcriptional
coregulators and chromatin modifiers that
underlie specific AR target gene functions
related to androgen-dependent prostatic
growth and/or differentiation and to
androgen-independent growth in prostate
cancer.
The inexorable process of selection
through which cancer cells develop resis-
tance to all types of anticancer agents
presents research and clinical oncolo-
gists with a daunting task. Through their
discovery of important reciprocal nega-
tive feedback involving AR and PTEN
loss/PI3K-AKT signaling in prostate
cancer, Carver et al. (2011) and Mulhol-
land et al. (2011) have not only set the
stage for rapid clinical testing of combina-
tion therapies aimed at these two
signaling networks, but they have also un-
masked the potential for future genetic
and pharmacologic approaches to under-
standing AR target gene functions and forCancer Cellidentifying new targets for prostate
cancer therapy.
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